Articles

Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA
Department of Haematology Guy’s and St Thomas’ Hospitals NHS Trust Hospital, London, UK
Department of Hematology, Necker University Hospital, Paris, France
Division of Hematology/Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, FL, USA
Hospital Nacional Edgardo Rebagliati Martins and Centro de Investigación de Medicina de Precision, Universidad de San Martin de Porres, Lima, Peru
Department of Hematology, University of São Paulo, Brazil
Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, and University of Birmingham, UK
John Theurer Cancer Center, Hackensack UMC, NJ, USA
National Centre for Human Retrovirology, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, UK
Center for Lymphoid Malignancies, Columbia University Irving Medical Center, New York, NY, USA
Kyowa Kirin, Princeton, NJ, USA
Kyowa Kirin, Princeton, NJ, USA
Kyowa Kirin, Princeton, NJ, USA
Kyowa Kirin, Princeton, NJ, USA
Kyowa Kirin, Princeton, NJ, USA
Warren Grant Magnuson Clinical Center, National Cancer Institute, Bethesda, MD, USA
Department of Haematology and National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, London, UK
Division of Hematology/Oncology, Department of Medicine, New York City Health + Hospitals/Kings County and SUNY Downstate Medical Center, Brooklyn, NY, USA
Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Vol. 104 No. 5 (2019): May, 2019 https://doi.org/10.3324/haematol.2018.205096